Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov;3(11):e157.
doi: 10.1371/journal.ppat.0030157.

HIV-1 group M conserved elements vaccine

Morgane Rolland  1 , David C Nickle, James I Mullins
Affiliations
Review

HIV-1 group M conserved elements vaccine

Morgane Rolland et al. PLoS Pathog. 2007 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests. The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Conservation of M Group Sequences across HIV-1 Proteins
The full lengths of each of the viral proteins containing 1st and/or 2nd tier CE are shown. The histogram indicates the tier of conservation for each segment of at least eight AAs in length, with tier number shown on the y-axis. 1st tier segments correspond to segments at least eight AAs long in which the AA at each site is found in more than 98% of HIVDB database sequences. 2nd tier include sites at which the most common AA is found in less than 98% of sequences in the database, but at which two AAs together make up more than 99% of the AAs found at that site in the database. For comparison, additional tiers of potential use for vaccine design are shown. 3rd tier expands the set to include two variable sites, and 4th tier includes n variable sites, each of which satisfy the criteria of having two AAs that together make up more than 99% of the AAs in the database. The 5th tier corresponds to peptides that have n variable sites that satisfy the criteria for 4th tier, but the requirement for conservation encompassed by the two AAs at each site is relaxed to more than 98%.
See this image and copyright information in PMC

References

    1. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol. 2005;79:1154–1163. - PMC - PubMed
    1. Doria-Rose N, Learn GH, Rodrigo AG, Nickle DC, Li F, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol. 2005;79:11214–11224. - PMC - PubMed
    1. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology. 2006;352:438–449. - PubMed
    1. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007;13:100–106. - PubMed
    1. Nickle DC, Rolland M, Jensen MA, Pond SLK, Deng W, et al. Coping with viral diversity in HIV vaccine design. PLoS Comput Biol. 2007;3:e75. doi: 10.1371/journal.pcbi.0030075. - DOI - PMC - PubMed

Publication types